reviewed april 2026|next review october 2026|88 physicians psi has verified|22652 published studies
Myostatin Inhibitor Peptides
Myostatin inhibitor peptides represent a class of compounds targeting the myostatin (GDF-8) pathway to promote muscle growth, with the dramatic phenotype of myostatin-knockout animals validated in biology but clinical translation proving more complex than the 'block myostatin, build muscle' hypothesis predicted.
Evidence landscape: 22652 published studies
22,652 published items. 46 human studies and 105 animal studies.
- 46 Human
- 105 Animal
- 49 Reviews
- 22452 Other research
No myostatin inhibitor is FDA-approved for any indication. Multiple clinical programs are active. Bimagrumab is the most clinically advanced (Phase II completed for obesity). ACE-031 development was paused for vascular safety. Domagrozumab and other antibodies are in various stages.
No myostatin inhibitor is commercially available. Follistatin (a naturally occurring (the body's own) myostatin binder) is available through research channels. All other approaches are investigational only.
This is a class page covering all approaches to myostatin pathway inhibition: antibodies (bimagrumab, domagrozumab), receptor traps (ACE-031), naturally occurring (the body's own) binders (follistatin, decorin), and gene therapy. The ActRII receptor regulates more than muscle. The 'muscle-only' hypothesis was too simple.
PSI Assessment
Myostatin-knockout mice grow twice normal muscle mass. Belgian Blue cattle, which carry natural myostatin mutations, are dramatically more muscular than standard breeds. The biology of myostatin as a negative regulator of muscle growth is among the most validated in all of physiology. Two decades of clinical trials attempting to exploit this biology have largely failed their primary endpoints. The disconnect between dramatic animal phenotypes and modest clinical results defines this field. Bimagrumab's Phase II obesity data (simultaneous fat loss and muscle gain) is the notable exception, reigniting interest in the pathway. Whether any myostatin inhibitor will achieve FDA approval for any indication remains open.
Myostatin-knockout mice grow twice normal muscle mass. Two decades of clinical trials have largely failed primary endpoints. Bimagrumab's obesity data is the notable exception.
The field encompasses multiple mechanistic approaches: anti-myostatin antibodies (domagrozumab, SRK-015/apitegromab), anti-ActRII antibodies (bimagrumab), soluble receptor traps (ACE-031), naturally occurring (the body's own) myostatin binders (follistatin, decorin), and gene therapy approaches. The central lesson from two decades of clinical trials is that the ActRII receptor system regulates far more than muscle. Broad ActRII inhibition affects vascular biology (ACE-031 halted for nosebleeds and telangiectasias), hematology (luspatercept received FDA approval for anemia through the same receptor family), and reproductive function (activin regulates FSH). The 'block myostatin, build muscle' hypothesis was too simple. More selective approaches are the current focus.
What the evidence supports
Myostatin-knockout animals consistently develop dramatically increased muscle mass across species. Multiple myostatin pathway inhibitors produce measurable lean mass increases in human trials (ACE-031 Phase I, bimagrumab Phase II). Bimagrumab Phase II obesity data showed simultaneous fat loss and muscle gain. The biology of myostatin as a negative regulator of muscle growth is established.
What is not yet established
Why most myostatin inhibitor trials have failed their primary functional endpoints despite producing biological activity (muscle mass increases). Whether more selective targeting can avoid the vascular and hematologic off-target effects of broad ActRII inhibition. The optimal therapeutic approach: antibodies versus receptor traps versus gene-based strategies. Whether the obesity application (bimagrumab) will advance to FDA approval.
Research Evidence
The findings below span the entire myostatin inhibitor class, from validated biology to the clinical translation challenges.
Evidence by condition
Evidence dimensions available for each condition Myostatin Inhibitor Peptides has been studied for.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Muscle Biology | ||||
| DMD / Neuromuscular Disease | ||||
| Sarcopenia | ||||
| Cachexia | ||||
| Obesity |
Myostatin-knockout animals consistently develop dramatically increased muscle mass across multiple species. This is one of the most validated phenotypes in muscle biology. The biological target is not in question.
The animal genetics are unambiguous. The challenge has been translating genetic myostatin absence (complete, lifelong) into pharmacological myostatin inhibition (partial, temporary) that produces meaningful clinical outcomes.
46 Human|105 Animal|49 Reviews
View all 22652 indexed studiesHow Myostatin Inhibitor Peptides Works
Myostatin (GDF-8) is a TGF-beta superfamily member that signals through the ActRIIB receptor, activating Smad2/3 to suppress myofiber hypertrophy. Inhibition approaches include anti-myostatin antibodies (domagrozumab, SRK-015), ActRIIB traps (ACE-031), anti-ActRII antibodies (bimagrumab), follistatin gene therapy, and recombinant follistatin peptide.
Myostatin is the body's muscle growth brake. It tells muscles to stop growing once they reach a certain size. Myostatin inhibitors release this brake, allowing muscles to grow larger and the body to shift energy from fat storage to muscle building. Animals without functional myostatin are dramatically more muscular.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Myostatin (GDF-8) signals through ActRIIB receptor, activating Smad2/3 to suppress myofiber hypertrophy. Inhibition approaches include anti-myostatin antibodies (domagrozumab, SRK-015), ActRIIB traps (ACE-031), anti-ActRII antibodies (bimagrumab), follistatin gene therapy, and recombinant follistatin peptide.
What is Myostatin Inhibitor Peptides being studied for?
Researchers are studying Myostatin Inhibitor Peptides across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Myostatin Inhibitor Peptides overall. This means a compound can have human studies for one condition but only animal data for another.
Muscle Biology
·Human TrialsThe biology of myostatin as a negative regulator of muscle growth is established across species. Multiple clinical trials have demonstrated that myostatin pathway inhibition increases lean mass in humans.
Limitations: Muscle mass increases have not consistently translated to functional improvement (strength, mobility, survival) in clinical trials.
DMD / Neuromuscular Disease
·Human TrialsMultiple clinical trials have tested myostatin inhibition in Duchenne muscular dystrophy. ACE-031 was halted for safety. Domagrozumab and other approaches are in development.
Limitations: No myostatin inhibitor is approved for DMD. The vascular safety signals from ACE-031 remain a concern for broad ActRII inhibition.
Sarcopenia
·Animal StudiesBimagrumab Phase II showed increased thigh muscle volume and lean body mass in sarcopenia. Functional improvement was less consistent.
Limitations: Whether increased muscle mass translates to meaningful functional improvement in elderly patients is debated across all sarcopenia trials.
Cachexia
·Animal StudiesCancer-related muscle wasting is a potential application for myostatin pathway inhibition. Animal study data supports the mechanism.
Limitations: Clinical trials in cachexia are limited. The complex metabolic environment of cancer may limit the efficacy of myostatin inhibition alone.
Obesity
·Human TrialsBimagrumab Phase II in obese type 2 diabetes patients showed 20% fat mass reduction with simultaneous 3.6% lean mass gain. The most compelling body composition drug data outside of GLP-1 agonists.
Limitations: Phase III confirmation needed. Whether the approach complements GLP-1 therapy is unknown.
Safety and Regulatory Status
FDA Status: No myostatin inhibitor is FDA-approved for any indication. Multiple clinical programs are active across different mechanisms and disease targets.
Availability: Follistatin is available through research channels. All pharmaceutical-grade myostatin inhibitors (bimagrumab, domagrozumab, apitegromab) are investigational only.
Class context: Safety concerns include effects on cardiac muscle, tendon and ligament strength relative to increased muscle force, vascular biology (ACE-031 halted), and reproductive function (activin regulates FSH). No myostatin inhibitor has completed the regulatory approval process.
Myostatin inhibitors are investigational. Safety concerns vary by mechanism: broad ActRII inhibition affects vascular biology and reproductive function. Myostatin-specific approaches may have narrower side-effect profiles. The heart is also a muscle, and chronic myostatin inhibition could affect cardiac physiology. No long-term safety data exists for any approach.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Myostatin Inhibitor Peptides discussion.
Comparison and Related Research
The myostatin inhibitor field includes multiple mechanistic approaches. Understanding the differences clarifies the landscape.
Head-to-head comparisons
Full research comparisons covering Myostatin Inhibitor Peptides and another peptide side by side.
Myostatin Inhibitor Peptides vs Follistatin
Follistatin binds multiple targets including myostatin. Pharmaceutical antibodies target myostatin specifically. Evidence-graded comparison for muscle research.
View full comparisonRelated compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.The landmark discovery paper for myostatin (GDF-8). Mice lacking the myostatin gene developed dramatically increased skeletal muscle mass, establishing myostatin as a negative regulator of muscle growth. This finding launched an entire field of research into myostatin inhibition as a therapeutic strategy for muscle-wasting conditions.McPherron AC et al., 1997 in Nature. View on PubMed
- 2.Authoritative review of the myostatin signaling pathway, covering the discovery, mechanism of action through the activin type II receptor system, natural inhibitors like follistatin, and the implications for therapeutic targeting. The review summarized the rationale for developing myostatin inhibitors for conditions including muscular dystrophy, sarcopenia, and cachexia.Lee SJ, 2004 in Annu Rev Cell Dev Biol. View on PubMed
- 3.First clinical trial of a myostatin-neutralizing antibody (stamulumab/MYO-029) in adults with muscular dystrophy. While the drug was well-tolerated, no significant improvements in muscle strength or function were observed, highlighting the challenge of translating the dramatic preclinical myostatin-knockout results into clinical benefit.Wagner KR et al., 2008 in Ann Neurol. View on PubMed
- 4.Phase II trial testing a myostatin antibody in older adults with a history of falls and low muscle strength. Treatment produced modest increases in lean body mass and some improvements in functional measures, providing proof-of-concept that myostatin inhibition could benefit age-related muscle loss, though the magnitude of effect was smaller than preclinical predictions.Becker C et al., 2015 in Lancet Diabetes Endocrinol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.